Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 145 No. 3940 (2015)

Time trends in avoidable cancer mortality in Switzerland and neighbouring European countries 1996–2010

  • Anita Feller
  • Michael Thomas Mark
  • Annik Steiner
  • Kerri M. Clough-Gorr
DOI
https://doi.org/10.4414/smw.2015.14184
Cite this as:
Swiss Med Wkly. 2015;145:w14184
Published
20.09.2015

Abstract

QUESTION UNDER STUDY: What are the trends in avoidable cancer mortality in Switzerland and neighbouring countries?

METHODS: Mortality data and population estimates 1996–2010 were obtained from the Swiss Federal Statistical Office for Switzerland and the World Health Organization Mortality Database (http://www.who.int/healthinfo/mortality_data/en/) for Austria, Germany, France and Italy. Age standardised mortality rates (ASMRs, European standard) per 100 000 person-years were calculated for the population <75 years old by sex for the following groups of cancer deaths: (1) avoidable through primary prevention; (2) avoidable through early detection and treatment; (3) avoidable through improved treatment and medical care; and (4) remaining cancer deaths. To assess time trends in ASMRs, estimated annual percentage changes (EAPCs) with 95% confidence intervals (95% CIs) were calculated.

RESULTS: In Switzerland and neighbouring countries cancer mortality in persons <75 years old continuously decreased 1996–2010. Avoidable cancer mortality decreased in all groups of avoidable cancer deaths in both sexes, with one exception. ASMRs for causes avoidable through primary prevention increased in females in all countries (in Switzerland from 16.2 to 20.3 per 100 000 person years, EAPC 2.0 [95% CI 1.4 to 2.6]). Compared with its neighbouring countries, Switzerland showed the lowest rates for all groups of avoidable cancer mortality in males 2008–2010.

CONCLUSION: Overall avoidable cancer mortality decreased, indicating achievements in cancer care and related health policies. However, increasing trends in avoidable cancer mortality through primary prevention for females suggest there is a need in Switzerland and its European neighbouring countries to improve primary prevention.

References

  1. Rutstein DD, Berenberg W, Chalmers TC, Child CG, 3rd, Fishman AP, Perrin EB. Measuring the quality of medical care. A clinical method. N Engl J Med. 1976;294(11):582–8.
  2. Charlton JR, Hartley RM, Silver R, Holland WW. Geographical variation in mortality from conditions amenable to medical intervention in England and Wales. Lancet. 1983;1(8326 Pt 1):691–6.
  3. Castelli A, Nizalova O. Avoidable mortality: What it means and how it is measured. Working Papers. 2011.
  4. Nolte E, McKee M. Does health care save lives? Avoidable mortality revisited: The Nuffield Trust; 2004.
  5. Mortality, cause of death - Data, Indicators [Internet]. Federal Statistical Office (FSO). [cited 7/9/2014]. Available from: http://www.bfs.admin.ch/bfs/portal/en/index/themen/14/02/04/key/01.html.
  6. Cancer – Data, Indicators [Internet]. Federal StatisticalOffice. 2015 [cited 01/02/2015].
  7. The population of Switzerland 2009. Neuchâtel: Federal Statistical Office (FSO), 2010.
  8. Herrmann C, Cerny T, Savidan A, Vounatsou P, Konzelmann I, Bouchardy C, et al. Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer. 2013;13:287.
  9. WHO mortality database [Internet]. World Health Organization (WHO). [cited 5/5/2013]. Available from: http://www.who.int/healthinfo/statistics/mortality_rawdata/en/.
  10. Simonato L, Ballard T, Bellini P, Winkelmann R. Avoidable mortality in Europe 1955–1994: a plea for prevention. J Epidemiol Community Health. 1998;52(10):624–30.
  11. Piers LS, Carson NJ, Brown K, Ansari Z. Avoidable mortality in Victoria between 1979 and 2001. Aust N Z J Public Health. 2007;31(1):5–12.
  12. Smailyte G, Pareigis L. Time trends in avoidable cancer mortality in Lithuania 1992–2008. Acta Medica Lituanica. 2011;18(4):156–60.
  13. Tobias M, Jackson G. Avoidable mortality in New Zealand, 1981–97. A N Z J Public Health. 2001;25(1):12–20.
  14. Kahi CJ, Imperiale TF. ACP Journal Club. Flexible sigmoidoscopy screening reduced colorectal cancer incidence and mortality in older adults. Ann Intern Med. 2012;157(6):JC3-.
  15. Koretz RL. ACP Journal Club. Once-only flexible sigmoidoscopy screening reduced colorectal cancer incidence and mortality. Ann Intern Med. 2010;153(8):JC4-.
  16. Libby G, Brewster DH, McClements PL, Carey FA, Black RJ, Birrell J, et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study. Br J Cancer. 2012;107(2):255–9.
  17. Shroff J, Thosani N, Batra S, Singh H, Guha S. Reduced incidence and mortality from colorectal cancer with flexible-sigmoidoscopy screening: A meta-analysis. World journal of gastroenterology: WJG. 2014;20(48):18466–76.
  18. Zorzi M, Fedeli U. Early effect of screening programmes on incidence and mortality rates of colorectal cancer. Gut. 2014.
  19. Doll R. Comparison between Registries. Age-Standardized Rates. In: Waterhouse J, Muir C, Correa P, Powell J, editors. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer; 1976. p. 453–9.
  20. WHO Global Report – Mortality Attributable to Tobacco. Geneva: World Health Organization (WHO), 2012.
  21. Health at a Glance: Europe 2014. Organisation for Economic Co-operation and Development (OECD), 2014.
  22. Zatonski W, Przewozniak K, Sulkowska U, West R, Wojtyla A. Tobacco smoking in countries of the European Union. Annals of agricultural and environmental medicine: AAEM. 2012;19(2):181–92.
  23. Graham H. Smoking prevalence among women in the European community 1950–1990. Social science & medicine. 1996;43(2):243–54.
  24. Schweizerische Gesundheitsbefragung 2012. Neuchâtel: Federal Statistical Office (FSO), 2013.
  25. Gallus S, Lugo A, Colombo P, Pacifici R, La Vecchia C. Smoking prevalence in Italy 2011 and 2012, with a focus on hand-rolled cigarettes. Preventive Medicine. 2013;56(5):314–8.
  26. Lampert T, von der Lippe E, Muters S. Prevalence of smoking in the adult population of Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013;56(5-6):802–8.
  27. Tilloy E, Cottel D, Ruidavets JB, Arveiler D, Ducimetiere P, Bongard V, et al. Characteristics of current smokers, former smokers, and second-hand exposure and evolution between 1985 and 2007. European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010;17(6):730–6.
  28. Health at a Glance: Europe 2012. Organisation for Economic Co-operation and Development (OECD), 2012.
  29. von Karsa L, Anttila A, Ronco G, Ponti A, Arbyn M, Segnan N, et al. Cancer screening in the European Union – Report on the implementation of the Council Recommendation on cancer screening. European Commission, 2008.
  30. Faisst K, Schilling J, Koch P. Health technology assessment of three screening methods in Switzerland. Int J Technol Assess Health Care. 2001;17(3):389–99.
  31. Jurgens V, Ess S, Phuleria HC, Fruh M, Schwenkglenks M, Frick H, et al. Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. Swiss Med Wkly. 2013;143:w13771.
  32. Haldemann K, Marbet U. Aktueller Stand des Kolonkarzinom-Screenings in der Schweiz. info@onkologie. 2013;4:30–2.
  33. Untiet S, Schmidt N, Low N, Petignat P. Gebärmutterhalskrebs-Screening in der Schweiz - aktueller Stand und neue Herausforderungen. Ther Umschau. 2013;70(4):223–30.
  34. Miles A, Cockburn J, Smith RA, Wardle J. A perspective from countries using organized screening programs. Cancer. 2004;101(5 Suppl):1201–13.
  35. Garattini S, La Vecchia C. Perspectives in cancer chemotherapy. Eur J Cancer. 2001;37(Suppl 8):S128–47.
  36. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283(22):2975–8.
  37. Einhorn LH. Treatment of testicular cancer: a new and improved model. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1990;8(11):1777–81.
  38. Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E. Western and eastern European trends in testicular cancer mortality. Lancet. 2001;357(9271):1853–4.
  39. Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118(12):3099–111.
  40. Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095–106.
  41. Horning SJ. The Cure of Hodgkin Lymphoma. 50 Years in Hematology: Research That Revolutionized Patient Care. 2008:16–7.
  42. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Research. 2008;68(21):8643–53.
  43. La Vecchia C, Levi F, Lucchini F, Kaye SB, Boyle P. Hodgkin’s disease mortality in Europe. Br J Cancer. 1991;64(4):723–34.
  44. Levi F, La Vecchia C, Lucchini F, Te VC, Franceschi S. Mortality from Hodgkin’s disease and other lymphomas in Europe, 1960–1990. Oncology. 1995;52(2):93–6.
  45. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Trends in mortality from Hodgkin’s disease in western and eastern Europe. Br J Cancer. 2002;87(3):291–3.
  46. Levi F, Lucchini F, Negri E, Barbui T, La Vecchia C. Trends in mortality from leukemia in subsequent age groups. Leukemia. 2000;14(11):1980–5.
  47. Mesle F, Vallin J. The effect of ICD-10 on continuity in cause-of-death statistics. The example of France. Population. 2008;63(2).
  48. Lutz JM, Pury P, Fioretta G, Raymond L. The impact of coding process on observed cancer mortality trends in Switzerland. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2004;13(1):77–81.
  49. Schmidlin K, Clough-Gorr KM, Spoerri A, Egger M, Zwahlen M, Swiss National C. Impact of unlinked deaths and coding changes on mortality trends in the Swiss National Cohort. BMC Med Inform Decis Mak. 2013;13:1.
  50. Donabedian A. Evaluating the quality of medical care. The Milbank memorial fund quarterly. 1966:166–206.
  51. Donabedian A. The quality of care: How can it be assessed? JAMA. 1988;260(12):1743–8.
  52. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care. 2003;15(6):523–30.

Most read articles by the same author(s)